Table 2.
Annual cost reductions based on base rate as a function of reduction in ESAs and IV iron arising from ferric citrate usage
| ESA reduction | IV iron reduction
|
||
|---|---|---|---|
| 0.30 | 0.40 | 0.50 | |
| 0.10 | 0.578 (0.428–0.740) |
0.621 (0.470–0.786) |
0.663 (0.508–0.825) |
| 0.20 | 1.047 (0.762–1.307) |
1.089 (0.796–1.346)a |
1.137 (0.846–1.402) |
| 0.30 | 1.522 (1.082–1.883) |
1.560 (1.124–1.925) |
1.604 (1.165–1.973) |
Notes: Cost reductions are expressed as median and 20th and 80th percentiles (in billion USD).
a
Most likely result.
Abbreviations: ESA, erythropoietin-stimulating agent; IV, intravenous.